Company intelligence / Profile preview

Pepper Global

Boston, Massachusetts, United Statespepper-global.com ↗

Ownership: Private
Development stage: Commercial

Overview

Pepper Bio has developed a proprietary transomics platform (COMPASS) that integrates multiple omics layers—including genomics, transcriptomics, proteomics, and phosphoproteomics—to identify novel drug targets and optimize therapies for previously untreatable diseases. The company partners with pharma/biotech firms for target identification and lead optimization. It plans to enter clinical trials soon but has not yet reported clinical results.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small moleculePeptides
Industry: Biotech

Partnerships

Merck Digital Sciences Studio (accelerator program participation)Dean Felsher Laboratory (customer/collaborator)Cyclerion Therapeutics (customer/collaborator)Lerociclib licensing deal—exclusive rights outside Asia-Pacific announced May 2024.

Beyond the preview

Go deeper on Pepper Global.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pepper Global.

Explore the full profile